Handelsbanken Fonder AB Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Handelsbanken Fonder AB reduced its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 74,300 shares of the company’s stock after selling 11,000 shares during the quarter. Handelsbanken Fonder AB’s holdings in Krystal Biotech were worth $13,396,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Norges Bank bought a new position in Krystal Biotech in the 4th quarter worth about $34,391,000. Soleus Capital Management L.P. boosted its stake in Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock worth $56,144,000 after purchasing an additional 141,400 shares in the last quarter. GAMMA Investing LLC boosted its stake in Krystal Biotech by 50,249.4% in the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company’s stock worth $21,878,000 after purchasing an additional 121,101 shares in the last quarter. Raymond James Financial Inc. bought a new position in Krystal Biotech in the 4th quarter worth about $15,989,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company’s stock worth $79,812,000 after purchasing an additional 71,200 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Chardan Capital reiterated a “buy” rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. Citigroup lowered their target price on shares of Krystal Biotech from $215.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, May 16th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $211.13.

Krystal Biotech Stock Up 1.0%

NASDAQ KRYS opened at $139.62 on Thursday. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34. The firm has a market capitalization of $4.03 billion, a P/E ratio of 46.70 and a beta of 0.65. The company has a 50-day moving average price of $147.52 and a 200-day moving average price of $162.29.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $88.18 million for the quarter, compared to analysts’ expectations of $98.66 million. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).